Q3 Sales Fall 20% to $27.2M as Niagen Swings to $1.2M Net Loss
NAGE is trading near its 52-week low of $2.31 (9.1% above the low).
Summary
Third-quarter net sales dropped to $27.2 million from $33.99 million a year earlier, and the company swung from $4.58 million of net income to a $1.17 million loss. Adjusted EBITDA collapsed to $0.5 million from $6.4 million, so the profitable quarter a year ago is gone. The one bright spot is the balance sheet: cash rose to $69.5 million from $66.7 million at June 30 on $2.6 million of quarterly operating cash flow, which buys time. Management is guiding full-year direct website revenue up 15-20% and overall e-commerce up about 5%, but expects the ingredient business to shrink on lower volume from key partners — the same pressure that drove the Q2 miss. The 4:30 p.m. ET call is where guidance detail and the ingredient outlook get tested.
At the time of this announcement, NAGE was trading at $2.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $199.4M. The 52-week trading range was $2.31 to $7.95. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: BusinessWire.